Group items tagged

Michael Omidi is a double-board certified Plastic & Reconstructive Surgeon. Dr. Michael M Omidi, MD is a Doctor primarily located in Beverly Hills, CA. He has 21 years of experience. Dr. Michael Omidi is a plastic surgeon in Beverly Hills, California and is affiliated with West Covina Medical Center.

Why should you wait to turn 21, when you can start using medical marijuana at just 18 years of age. In this video we will explain you how you can start using medical cannabis using your medical marijuana recommendation without any state interference or legal complications.

Prohibition has finally come to an end, allowing users 21 and older to start buying cannabis from state dispensaries. And amidst the Jeff Sessions led chaos endangering the future of cannabis use by the federal government, most counties have proceeded to fulfill their promise of legal marijuana undeterred. But for the state's medical users, there's a slight snag.

The year 2018 would prove to be a landmark year for California, the home of the American cannabis culture. The new year would see some major laws would come into effect and nothing will ever be the same again. In just 3 days, the golden state would make a transition to a sanctuary state waive the fee for first-time students in community colleges and witness an increase in minimum wages. Not to forget the historic step to legalize recreational cannabis for users who are 21 years and older.

Britain called on Sunday (November 21) for international action on the issue of medical devices such as oximeters that work better on people with lighter skin, saying the disparities may have cost lives of ethnic minority patients during the Covid-19 pandemic. Health secretary Sajid Javid said he had commissioned a review of the issue after learning that oximeters, which measure blood oxygen levels and are key to assessing Covid patients, give less accurate readings for patients with darker skin. "This is systemic across the world. This is about a racial bias in some medical instruments. It's unintentional but it exists and oximeters are a really good example of that," Javid said during an interview with the BBC. Asked whether people may have died of Covid-19 as a result of the flaw, Javid said: "I think possibly yes. I don't have the full facts." He said the reason for the discrepancies was that a lot of medical devices, drugs, procedures and textbooks were put together in white majority countries.

A new study has revealed that public trust in services provided by local pharmacies ranks highest in the UK, although confidence in the NHS has nosedived following the pandemic. The 2022 Edelman Trust Barometer report published on Wednesday (April 21) found that around 78 per cent of respondents trust their local pharmacies, the highest for any provider cited in the survey. Besides, 72 per cent said pharmacists are among the most trusted to tell the truth about health matters and protect public health, almost similar to 'my doctor' (75%) and health experts (74%). Just under half of them said the pandemic has decreased their confidence that the NHS is well-equipped in handling major health crisis. The survey also revealed that 60 per cent think they lack access to high-quality healthcare.

Tough times for community pharmacies in England are far from over as the industry continues to grapple with major gaps in the workforce. Even though the latest figures released by the Health Education England (HEE) Community Pharmacy Workforce Survey 2021 showed doubling of pharmacist vacancy rate in England to 8 per cent between 2017 and 2021, it flagged the contractors' difficulty level in filling up these positions. The survey report showcased changes in the size and make-up of the community pharmacy workforce since the last survey conducted in 2017. It revealed that 56 per cent of pharmacy contractors reported high difficulty level in recruiting pharmacists, up from 21 per cent in the earlier survey. Moreover, a greater proportion - 60 per cent of contractors found filling up the pharmacy technician role 'fairly' or 'very' difficult. Other roles in the sector considered difficult to fill included accuracy checkers and trained dispensing assistants, both at 58 per cent.

The Indian government has suspended manufacturing in over 40 pharmaceutical companies based on a risk-based assessment conducted earlier in the year across 162 firms, according to the data provided by Union Health Minister Mansukh Mandaviya in Parliament on Thursday (Aug. 10). "Overall, a sum of 143 show-cause notices has been issued," Mandaviya said. There have been numerous recent incidents involving accusations from foreign countries regarding the contamination of syrups, eye drops, and ointments manufactured in India. Countries such as the Gambia, Uzbekistan, and Cameroon have linked the deaths of 70, 18, and six children, respectively, to cough syrups contaminated in India. Licenses for specific products have been either temporarily suspended or fully revoked for an additional 66 companies. In one case, an FIR has been registered, and in 21 cases, warning letters have been issued following inspections by both the Central Drugs Standard Control Organization and State authorities, the Minister added. Meanwhile, the Indian government has mandated rigorous testing for cough syrups before export. Starting June 1, any cough syrup must possess a government laboratory-issued certificate of analysis before being exported, the government said in a notice dated May 22.

The government has launched a consultation into radically changing the Statutory Scheme for branded medicines (known as the Statutory Scheme). The consultation comes as delicate negotiations for replacing the alternative Voluntary Scheme are underway, potentially undermining these talks, while also further damaging industry confidence in the UK as a viable place to research, launch and supply medicine. The government proposals seek to hold average revenue clawback rates under the Statutory Scheme at historic highs of between 21-27%, compared to the pre-pandemic averages of 9.4% for the Statutory Scheme (2019-2021), and 6.88% for the Voluntary Scheme (2014-2021). The accompanying cost-benefit analysis ignores any negative impact this may have on medicine supply and wrongly claims it will boost investment. The consultation comes on the heels of government data last week showing UK life sciences foreign direct investment (FDI) fell by 47% between 2021 and 2022, down by £900m year on year. This large fall in investment coincided with a rise in the main UK clawback rate under the Voluntary Scheme from 5% to 15%, and led to the UK falling from 2nd to 9th out of 18 comparator countries for life sciences FDI in 2022. The Voluntary Scheme clawback rate now sits at a record 26.5% in 2023.

The Royal Pharmaceutical Society (RPS) has published a consultation to review the 'Professional standards for the reporting, learning, sharing, taking action and review of incidents error reporting' in collaboration with Association of Pharmacy Technicians UK and Pharmacy Forum of Northern Ireland. The consultation is open from 21 April 2023 until 2 June 2023 and are due to be published in early 2024. All three professional leadership bodies are calling for contributions from anyone using the standards to ensure they are clear, current, relevant and fit for purpose. "The review affects all pharmacists, pharmacy technicians, trainees and members of the pharmacy team working in all sectors across the UK," RPS said. "The standards may also be of interest to the public, people who use pharmacy and healthcare services, healthcare and professionals working with pharmacy teams.

The University of Lincoln has clinched the top spot on The Guardian's 2024 list for pharmacy and pharmacology studies. This marks a significant advancement from its second-place position in the 2023 rankings, where Ulster University had secured the leading position. Interestingly, Ulster has moved down to claim the second spot this year. Forty universities were assessed using eight criteria, which encompass student satisfaction with teaching, the effectiveness of feedback from instructors, student-to-staff ratio, expenditure per student (excluding academic staff costs), and the average UCAS scores of entrants under 21. Also included were the effectiveness of teaching methods, the proportion of students securing graduate-level employment or pursuing further studies within 15 months of graduation, and the percentage of first-year students progressing into their second year. Among the 40 universities in the ranking list, the University of Lincoln achieved a perfect score of 100 out of 100, followed by Ulster (96.2), Portsmouth (87.9), Leeds (86.3), Glasgow (85.7), Sunderland (84.3), St George's (84.3), Aberdeen (81.3), UCL (81), and Queen's, Belfast (80.1).

All companies must send their accounts to Companies House each year. Recent evidence suggests that UK companies are increasingly struggling to file their accounts on time, with around 213,000 private companies reportedly missing their deadline in 2019-2020, resulting in over £93 million of penalties being issued. Over a fifth of companies that filed their accounts late that year had also filed late in the previous year. Under the Companies Act 2006 ("the Act"), the deadline for private companies to file their annual accounts is nine months from the end of the accounting reference period. There are slightly different rules for filing your first set of annual accounts and if these cover a period of more than 12 months, you must deliver them to Companies House within 21 months of the date of incorporation or 3 months from the accounting reference date, whichever is longer. Not filing your accounts at Companies House in a timely manner is also a criminal offence (under section 451 of the Act) and directors can be personally fined in the criminal courts. It is likely to come as a shock to most company directors who receive a summons to attend the Magistrates' Court in Cardiff for a criminal prosecution, particularly directors in larger pharmacy companies where directors are often detached from the preparation of accounts and senior financial staff and accountants are instructed to take care of such matters.

The widely-held concept that levels of "good" cholesterol in the blood can indicate heart disease risk is not equally true for Blacks and whites, and the measure itself may be of less value than previously thought, according to a U.S. study published on Monday (November 21). Various types of cholesterol are thought to have either healthy or unhealthy effects. Low levels of so-called "good" high-density lipoprotein (HDL) cholesterol were linked with higher odds for developing cardiac problems in the long-term study - but only in white participants, the study published in the Journal of the American College of Cardiology found. In contradiction to what has generally been assumed, low HDL levels did not confer any higher risk of heart disease in Black people, researchers said. Among white people, however, those with HDL levels below 40 milligrams per deciliter had a 22% higher risk for coronary heart disease compared with those whose HDL levels were higher. High HDL levels (above 60 mg/dL), which are thought to be protective, were not linked with lower coronary heart disease risks in either race, researchers found.

The Pharmaceutical Services Negotiating Committee (PSNC) has announced the margin delivery rates will increase from October as the agreed £100m write off is implemented. "The baseline margin allowance will remain £800m per year in 2022/23 and 2023/24," said PSNC. "Margin levels in the last two full years (2020/21 and 2021/22), as measured by the Margin Survey of independent pharmacies, were in excess of the baseline allowance, meaning that an excess was accrued." As new services have been introduced and take up of these has accelerated, the amount of unallocated funding left in the CPCF is now less than it previously was. As such, the value of the Transitional Payments will decrease from its current level. Some of the unallocated funding remaining in 2023/24 will be repurposed into a Flat Payment for all contractors (see details below). Over the course of the second half of 2022/23, the value of the Transitional Payments will be phased down. This will start in October 2022 with a reduction in payment levels to approximately 85% of the current level, as shown in the following table:

The NHS has made major improvements across long waits, urgent and emergency services, and cancer care, latest performance figures published on Thursday (11) have shown. The number of patients waiting more than 18 months fell to 10,737 by April - down by more than 90 per cent from 124,911 in September 2021 and by more than four-fifths since the start of January when there were 54,882. Around half of NHS trusts in England have no patients on their elective care waiting lists apart from those who have chosen to wait longer. More than one in five (21%) trusts had completely eliminated 18-month waits. However, the overall waiting list has risen to over 7.3 million entries in England. "I promised I would cut NHS waiting lists and we are delivering," Prime Minister Rishi Sunak said. "Reducing 18-month waits by over 90 per cent is huge progress, and it is testament to the hard work of NHS staff who have achieved this despite one of the busiest winters on record. "We still have work to do, but backed by record government investment and the ongoing efforts of the NHS, I am confident we will get patients the care they need more quickly." Ambulance response rates have improved to their fastest in two years, with average category two response times now at 28.5 minutes and category one at 8 mins. The 62-day cancer backlog has fallen for the first time since before the pandemic, with those waiting two months or more down from 21,823 at the end of the last financial year (March 2022) to 19,248 at the end of this March (2023). This is down almost 15,000 from a peak of 34,000 in July 2022.

The Taskforce report recognises the important role of community pharmacy and pharmacy teams, and in particular, the fact that they often have most contact with individuals who are receiving medication assisted treatment, commented the Royal Pharmaceutical Society (RPS) on the publication of the Scottish Drug Deaths Taskforce's final report. The final report published on Thursday (June 21) follows four years of work developing and implementing a programme of actions to tackle the rising number of drug deaths in Scotland. RPS, as pharmacy's professional leadership body in Scotland and the rest of Great Britain, has positively engaged with the Taskforce as it carried out its work. Last year, RPS published 'Pharmacy's role in reducing harm and preventing drugs deaths (Scotland)' which contained 14 key recommendations. Many of the recommended actions within the Taskforce's report align with RPS policy.

Long waits for an ambulance or surgery led to the death of 112 people, and nearly 8,000 more people suffered harm while waiting for help in England last year. The data from NHS England, obtained by The Guardian, show that patient deaths arising directly from care delays have risen more than fivefold over the last three years. In 2019, there were 21 patient deaths due to NHS care delays, and 96 people suffered "severe harm" as compared to 152 last year. Adult mental health care was mostly affected with 471 patients experiencing harm due to delays, followed by childbirth care (253), eye problems (221), and trauma and general surgery (207). There has been increase of 97 percent in the overall number of people suffering some degree of harm, from 3,979 in 2019 to 7,856 in 2022.

The US Food and Drug Administration (FDA) has approved the Novartis drug, Cosentyx, (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. HS is a chronic, progressive and painful disease which affects one in 100 people worldwide, and has limited treatment options. "Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS," said the Swiss company. The FDA approval was based on robust Phase III data (SUNSHINE and SUNRISE studies) in which Cosentyx showed rapid relief from HS symptoms as early as Week 21.

There were an estimated 408,700 hospital admissions due to smoking in 2022-23, an increase of 4.8 per cent from 389,800 in 2021-22, latest statistics published by NHS England have shown. In 2020-21, there were 314,100 admissions attributed to smoking, which was consistent with fewer hospital admissions overall that year, according to the health service's Statistics on Public Health, 2023 report. However, smoking-related admissions in each of the past three years remained lower than in 2019-20, prior to the Covid pandemic, when there were 446,400 cases. Smoking accounted for around one in six (16 per cent) of all hospital admissions for respiratory diseases last year, eight per cent of all admissions for cancers and seven percent of admissions for cardiovascular diseases.

The UK Health Security Agency (UKHSA) has raised alarm over rising cases of extensively antibiotic-resistant Shigella infections, mainly in gay, bisexual, and other men who have physical relationship with men (GBMSM). There has been a 53 per cent increase in cases since the beginning of 2023, mostly driven by a cluster of antibiotic resistant strain called Shigella sonnei, with 97 cases reported this year until November, compared to just four cases last year. According to UKHSA, Shigella sonnei infections are difficult to treat as the strain does not respond to the antibiotics typically used to treat the bacteria. While it has been found across England, cases are concentrated in London (45), the North West (21) and South East (12). Shigella is an infectious gut infection that can cause symptoms like diarrhoea (sometimes mixed with blood), stomach cramps and fever, which are commonly mistaken for food poisoning.